TipRanks
Exelixis (CH:EX9)
:EX9
Switzerland Market
EX9
Exelixis
RESEARCH TOOLSreports

Exelixis (EX9) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

EX9 Analyst Ratings

Hold
15Ratings
Hold
4 Buy
10 Hold
1 Sell
Based on 15 analysts giving stock ratings to
Exelixis
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EX9 Stock 12 Month Forecast

Average Price Target

―
Based on 15 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is CHF42.62 with a high forecast of CHF52.45 and a low forecast of CHF33.60. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF52.45Average Price TargetCHF42.62Lowest Price TargetCHF33.60
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on CH:EX9
Gregory Renza
Truist Financial
Truist Financial
―
Hold
―
Reiterated
09/14/26
Analysts Offer Insights on NA Companies: Exelixis (NASDAQ: EXEL) and Resolution Minerals Ltd. Sponsored ADR (NASDAQ: RML)
Bank of America Securities Analyst forecast on CH:EX9
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF33.6
Sell
―
Reiterated
09/11/26
Analysts' Opinions Are Mixed on These NA Stocks: SpaceX (NASDAQ: SPCX), Insmed (NASDAQ: INSM) and Exelixis (NASDAQ: EXEL)
BMO Capital Analyst forecast on CH:EX9
David Lebowitz
BMO Capital
BMO Capital
CHF44.26
Hold
―
Reiterated
09/11/26
Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed
Stifel Nicolaus Analyst forecast on CH:EX9
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
―
Hold
―
Reiterated
09/11/26
FDA-Driven Zanza Delay Keeps Exelixis Fairly Valued, Supporting Willey’s Hold Rating
William Blair Analyst forecast on CH:EX9
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
09/11/26
Analysts Offer Insights on NA Companies: Exelixis (NASDAQ: EXEL) and HEICO (NYSE: HEI)
Guggenheim Analyst forecast on CH:EX9
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
09/01/26
Guggenheim Remains a Hold on Exelixis (EXEL)
Barclays Analyst forecast on CH:EX9
Etzer Darout
Barclays
Barclays
CHF40.16
Hold
―
Reiterated
08/06/26
Barclays Reaffirms Their Hold Rating on Exelixis (EXEL)
Wells Fargo Analyst forecast on CH:EX9
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
CHF40.16→CHF40.98
Hold
―
Assigned
08/06/26
Exelixis (EXEL) Gets a Hold from Wells Fargo
RBC Capital Analyst forecast on CH:EX9
Leonid Timashev
RBC Capital
RBC Capital
CHF37.7
Hold
―
Reiterated
08/06/26
RBC Capital Sticks to Their Hold Rating for Exelixis (EXEL)
Leerink Partners Analyst forecast on CH:EX9
Andrew Berens
Leerink Partners
Leerink Partners
CHF42.62
Hold
―
Downgraded
08/06/26
Exelixis downgraded to Market Perform from Outperform at LeerinkExelixis downgraded to Market Perform from Outperform at Leerink
Morgan Stanley Analyst forecast on CH:EX9
Sean Laaman
Morgan Stanley
Morgan Stanley
CHF43.44
Hold
―
Reiterated
08/06/26
Morgan Stanley Sticks to Its Hold Rating for Exelixis (EXEL)
TD Cowen Analyst forecast on CH:EX9
Yaron Werber
TD Cowen
TD Cowen
CHF45.08
Buy
―
Reiterated
08/05/26
Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut
Goldman Sachs Analyst forecast on CH:EX9
Paul Choi
Goldman Sachs
Goldman Sachs
CHF52.45
Buy
―
Reiterated
08/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)
H.C. Wainwright Analyst forecast on CH:EX9
Robert Burns
H.C. Wainwright
H.C. Wainwright
CHF45.9
Buy
―
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Santhera Pharmaceuticals Holding (Other OTC: SPHDF)
UBS Analyst forecast on CH:EX9
Ashwani Verma
UBS
UBS
CHF35.24→CHF42.62
Hold
―
Assigned
07/02/26
Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Exelixis (NASDAQ: EXEL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on CH:EX9
Gregory Renza
Truist Financial
Truist Financial
―
Hold
―
Reiterated
09/14/26
Analysts Offer Insights on NA Companies: Exelixis (NASDAQ: EXEL) and Resolution Minerals Ltd. Sponsored ADR (NASDAQ: RML)
Bank of America Securities Analyst forecast on CH:EX9
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF33.6
Sell
―
Reiterated
09/11/26
Analysts' Opinions Are Mixed on These NA Stocks: SpaceX (NASDAQ: SPCX), Insmed (NASDAQ: INSM) and Exelixis (NASDAQ: EXEL)
BMO Capital Analyst forecast on CH:EX9
David Lebowitz
BMO Capital
BMO Capital
CHF44.26
Hold
―
Reiterated
09/11/26
Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed
Stifel Nicolaus Analyst forecast on CH:EX9
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
―
Hold
―
Reiterated
09/11/26
FDA-Driven Zanza Delay Keeps Exelixis Fairly Valued, Supporting Willey’s Hold Rating
William Blair Analyst forecast on CH:EX9
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
09/11/26
Analysts Offer Insights on NA Companies: Exelixis (NASDAQ: EXEL) and HEICO (NYSE: HEI)
Guggenheim Analyst forecast on CH:EX9
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
09/01/26
Guggenheim Remains a Hold on Exelixis (EXEL)
Barclays Analyst forecast on CH:EX9
Etzer Darout
Barclays
Barclays
CHF40.16
Hold
―
Reiterated
08/06/26
Barclays Reaffirms Their Hold Rating on Exelixis (EXEL)
Wells Fargo Analyst forecast on CH:EX9
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
CHF40.16→CHF40.98
Hold
―
Assigned
08/06/26
Exelixis (EXEL) Gets a Hold from Wells Fargo
RBC Capital Analyst forecast on CH:EX9
Leonid Timashev
RBC Capital
RBC Capital
CHF37.7
Hold
―
Reiterated
08/06/26
RBC Capital Sticks to Their Hold Rating for Exelixis (EXEL)
Leerink Partners Analyst forecast on CH:EX9
Andrew Berens
Leerink Partners
Leerink Partners
CHF42.62
Hold
―
Downgraded
08/06/26
Exelixis downgraded to Market Perform from Outperform at LeerinkExelixis downgraded to Market Perform from Outperform at Leerink
Morgan Stanley Analyst forecast on CH:EX9
Sean Laaman
Morgan Stanley
Morgan Stanley
CHF43.44
Hold
―
Reiterated
08/06/26
Morgan Stanley Sticks to Its Hold Rating for Exelixis (EXEL)
TD Cowen Analyst forecast on CH:EX9
Yaron Werber
TD Cowen
TD Cowen
CHF45.08
Buy
―
Reiterated
08/05/26
Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut
Goldman Sachs Analyst forecast on CH:EX9
Paul Choi
Goldman Sachs
Goldman Sachs
CHF52.45
Buy
―
Reiterated
08/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)
H.C. Wainwright Analyst forecast on CH:EX9
Robert Burns
H.C. Wainwright
H.C. Wainwright
CHF45.9
Buy
―
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Santhera Pharmaceuticals Holding (Other OTC: SPHDF)
UBS Analyst forecast on CH:EX9
Ashwani Verma
UBS
UBS
CHF35.24→CHF42.62
Hold
―
Assigned
07/02/26
Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Exelixis (NASDAQ: EXEL)
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exelixis

3 Months
Robert BurnsH.C. Wainwright
Success Rate
15/18 ratings generated profit
83%
Average Return
+8.39%
Copying Robert Burns's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +8.39% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
18/18 ratings generated profit
100%
Average Return
+37.87%
Copying Robert Burns's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +37.87% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
18/18 ratings generated profit
100%
Average Return
+58.84%
Copying Robert Burns's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +58.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EX9 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
9
8
7
6
6
Hold
17
14
15
19
22
Sell
0
1
1
2
2
Strong Sell
0
0
0
0
0
total
26
23
23
27
30
In the current month, EX9 has received 6 Buy Ratings, 22 Hold Ratings, and 2 Sell Ratings. EX9 average Analyst price target in the past 3 months is 42.62.
Each month's total comprises the sum of three months' worth of ratings.

EX9 Financial Forecast

EX9 Earnings Forecast

Next quarter’s earnings estimate for EX9 is CHF0.72 with a range of CHF0.62 to CHF0.78. The previous quarter’s EPS was CHF0.74. EX9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year EX9 has Performed in-line its overall industry.
Next quarter’s earnings estimate for EX9 is CHF0.72 with a range of CHF0.62 to CHF0.78. The previous quarter’s EPS was CHF0.74. EX9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year EX9 has Performed in-line its overall industry.

EX9 Sales Forecast

Next quarter’s sales forecast for EX9 is CHF528.43M with a range of CHF513.34M to CHF546.67M. The previous quarter’s sales results were CHF511.44M. EX9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year EX9 has Performed in-line its overall industry.
Next quarter’s sales forecast for EX9 is CHF528.43M with a range of CHF513.34M to CHF546.67M. The previous quarter’s sales results were CHF511.44M. EX9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year EX9 has Performed in-line its overall industry.

EX9 Stock Forecast FAQ

What is CH:EX9’s average 12-month price target, according to analysts?
Based on analyst ratings, Exelixis’s 12-month average price target is 42.62.
    What is CH:EX9’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:EX9, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Exelixis a Buy, Sell or Hold?
        Exelixis has a consensus rating of Hold, which is based on 4 buy ratings, 10 hold ratings and 1 sell ratings.
          What is Exelixis’s share price target?
          The average share price target for Exelixis is 42.62. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF52.45 ,and the lowest forecast is CHF33.60. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Exelixis?
            Exelixis’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.
              How can I buy shares of Exelixis?
              To buy shares of CH:EX9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.